83/100BWest Pharmaceutical Services stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for West Pharmaceutical Services is 427.43, 3.7% above the current price of 412.06. Their targets range from 390.00 to 475.00.
Of the 8 firms that rated West Pharmaceutical Services in the past 12 months, 8 rate it buy or strong buy, 0 hold and 0 sell or strong sell (each firm at its latest rating): a Strong buy consensus.
Analysts' 1-year price targets range from 390.00 to 475.00, with an average of 427.43.
| Buy | 8 | |
| Hold | 0 | |
| Sell | 0 |
12-month price target
| Highest target | 475.00 |
| Average target | 427.43 |
| Lowest target | 390.00 |
| Current price | 412.06 |
West Pharmaceutical Services price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their West Pharmaceutical Services price target and rating?
How analysts rate West Pharmaceutical Services, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
8 of 8 firms rate it buy now, against 3 of 4 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
West Pharmaceutical Services analyst upgrades, downgrades and price targets
The latest rating change came on 22 September 2026, when Morgan Stanley upgraded West Pharmaceutical Services from Equal Weight to Overweight. Its price target is 400.00, from 365.00. The most recent new target came from Jefferies on 2 November 2026: 475.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 2 Nov 2026 | Jefferies David Windley | — | 295.00 → 475.00 | +61.0% | 412.62 |
| 7 Oct 2026 | Barclays Luke Sergott | Reiterated · Overweight | 400.00 → 440.00 | +10.0% | 372.64 |
| 22 Sept 2026 | Morgan Stanley Kallum Titchmarsh | Upgraded · Equal Weight → Overweight | 365.00 → 400.00 | +9.6% | 361.73 |
| 9 Sept 2026 | UBS | Reiterated · Buy | 340.00 → 415.00 | +22.1% | 338.06 |
| 27 Jul 2026 | Evercore ISI | Reiterated · Outperform | 410.00 → 425.00 | +3.7% | 333.12 |
| 13 Jul 2026 | BNP Paribas | — | 447.00 | — | 353.71 |
| 9 Jul 2026 | Morgan Stanley | Reiterated · Equal Weight | 315.00 → 365.00 | +15.9% | 353.68 |
| 6 Jul 2026 | Evercore ISI Daniel Markowitz | Reiterated · Outperform | 320.00 → 410.00 | +28.1% | 359.27 |
| 2 Jul 2026 | KeyBanc | Reiterated · Overweight | 390.00 | — | 365.00 |
| 9 Jun 2026 | Barclays Luke Sergott | Upgraded · Equal Weight → Overweight | 310.00 → 400.00 | +29.0% | 319.75 |
| 27 Apr 2026 | Morgan Stanley | — | 285.00 → 315.00 | +10.5% | 306.39 |
| 27 Apr 2026 | Barclays | Reiterated · Equal Weight | 265.00 → 310.00 | +17.0% | 306.16 |
| 13 Feb 2026 | UBS Dan Leonard | — | 355.00 → 340.00 | -4.2% | 246.60 |
| 13 Feb 2026 | Deutsche Bank | — | 345.00 → 315.00 | -8.7% | 247.49 |
| 13 Feb 2026 | Barclays Luke Sergott | Reiterated · Equal Weight | 325.00 → 265.00 | -18.5% | 243.61 |
| 10 Feb 2026 | Jefferies David Windley | — | 295.00 | — | 249.97 |
| 3 Feb 2026 | Evercore ISI Daniel Markowitz | Reiterated · Outperform | 390.00 → 320.00 | -17.9% | 237.88 |
| 1 Dec 2025 | Morgan Stanley | — | 285.00 | — | 274.14 |
West Pharmaceutical Services EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Analysts expect West Pharmaceutical Services's EPS to grow 20.5% a year until 2028. Over the last 5 years it grew 8.3% a year, and over the last 3 years it fell 4.2%.
Analysts expect West Pharmaceutical Services's revenue to grow 8.3% a year until 2028. Over the last 5 years it grew 7.4% a year, and over the last 3 years 2.1%.
Revenue
EPS
Does West Pharmaceutical Services beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 16.6% off the result, either way, and their revenue estimate 3.7%, over the last 12 quarters.
- EPS beats
- 86 / 128
- Revenue beats
- 78 / 120
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +14.5%
- Since
- February 1993
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 29 Oct 2026 | 2.20 | 2.66 | +20.9% | 827.12M | 874.50M | +5.7% |
| Q2 FY2026 | 23 Jul 2026 | 2.08 | 2.37 | +13.9% | 839.98M | 872.30M | +3.8% |
| Q1 FY2026 | 23 Apr 2026 | 1.68 | 2.13 | +26.8% | 780.31M | 844.90M | +8.3% |
| Q4 FY2025 | 12 Feb 2026 | 1.83 | 2.04 | +11.5% | 794.89M | 805.00M | +1.3% |
| Q3 FY2025 | 23 Oct 2025 | 1.68 | 1.96 | +16.7% | 785.71M | 804.30M | +2.4% |
| Q2 FY2025 | 24 Jul 2025 | 1.51 | 1.84 | +21.9% | 726.09M | 766.20M | +5.5% |
| Q1 FY2025 | 24 Apr 2025 | 1.22 | 1.45 | +18.9% | 712.98M | 698.00M | -2.1% |
| Q4 FY2024 | 13 Feb 2025 | 1.71 | 1.82 | +6.4% | 740.47M | 748.80M | +1.1% |
| Q3 FY2024 | 24 Oct 2024 | 1.50 | 1.85 | +23.3% | 709.62M | 746.90M | +5.3% |
| Q2 FY2024 | 25 Jul 2024 | 1.74 | 1.52 | -12.6% | 729.36M | 702.00M | -3.8% |
| Q1 FY2024 | 25 Apr 2024 | 1.26 | 1.56 | +23.8% | 670.62M | 695.40M | +3.7% |
| Q4 FY2023 | 15 Feb 2024 | 1.78 | 1.83 | +2.8% | 739.47M | 732.00M | -1.0% |
West Pharmaceutical Services stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If West Pharmaceutical Services's earnings grow at the 17.7% a year analysts expect to FY2028, then 15.0% a year, it would earn about 15.72 a share in FY2030. At the P/E it has traded at over the last five years (29.9 to 52.7) that is 469.43 to 828.27 a share, or 684.71 at its average P/E of 43.6. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 9.49 | 283.43 | 413.42 | 500.10 |
| FY2027 | 10.36 | 309.46 | 451.38 | 546.01 |
| FY2028 | 11.88 | 354.95 | 517.74 | 626.29 |
| FY2029 (extrapolated) | 13.67 | 408.20 | 595.40 | 720.23 |
| FY2030 (extrapolated) | 15.72 | 469.43 | 684.71 | 828.27 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow 15.0% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (29.9, 43.6, 52.7).
Is West Pharmaceutical Services stock undervalued or overvalued?How does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
West Pharmaceutical Services's P/E of 45.9 is above the middle of its 5-year range (24.7 to 59.2, median 42.3). Analysts expect faster growth than in recent years, which can explain part of the high P/E. Buyers pay less for each point of growth than usual: a PEG of 2.2 on expected growth against 5.1 on its median P/E and past five years' growth. At its usual P/E (42.3 × EPS of 8.97), West Pharmaceutical Services's fair value is 379.45; the price, 412.06, is 8.6% above it. Its forward P/E, on the consensus for FY2026, is 43.4.
Fair value is the usual (median) P/E of the last five years times the earnings per share of the last twelve months; the ends of the bar are the same earnings at its lowest and highest P/E of those years (24.7 and 59.2). The price against its P/E range
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 45.94
- Five-year median P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 42.30
- Five-year P/E range
- 24.7 – 59.2
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 43.42
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 2.60
- To the average targetWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
- +3.7%
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 235.690 | 464.49205Price 235.69627 | +97.1% | |
| 28.860 | 56.2634Price 28.8696 | +94.9% | |
| 199.110 | 384.58163Price 199.112,644 | +93.1% | |
| 123.990 | 237.24178Price 123.99297 | +91.3% | |
| 157.820 | 297.58169Price 157.82471 | +88.6% | |
| 162.670 | 305.52160Price 162.67396 | +87.8% | |
| 216.610 | 405.38304Price 216.61507 | +87.1% |
Furthest below the fair value on each stock's page, updated every day.